Axsome Therapeutics (NASDAQ: AXSM ) has been on an evolution moving from being a development-stage company into a neuroscience company. Three of its drugs are now being marketed and has a rich late-stage pipeline. Q3 2025 earningsGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu ...